These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 1981860)

  • 1. [Pharmacology of a new antihypertensive agent, metazosin (Kenosin)].
    Trcka V; König J; Mácová S; Smíd M; Helfert I; Votavová M; Remesová J; Nezádalová E
    Cesk Farm; 1990 Jul; 39(6):266-74. PubMed ID: 1981860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review.
    Weidinger G
    Arzneimittelforschung; 1995 Nov; 45(11):1166-71. PubMed ID: 8929232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CI-926 (3-[4-[4-(3-methylphenyl)-1-piperazinyl]butyl]-2,4-imidazolinedione): antihypertensive profile and pharmacology.
    Ryan MJ; Bjork FA; Cohen DM; Coughenour LL; Major TC; Mathias NP; Mertz TE; Olszewski BJ; Singer RM; Evans DB
    J Pharmacol Exp Ther; 1986 Aug; 238(2):473-9. PubMed ID: 2874210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological studies of N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899), a new long-acting antihypertensive vasodilator.
    Baldoli E; Bianchi G; Corsico N; Di Francesco GF
    Arzneimittelforschung; 1985; 35(5):818-26. PubMed ID: 2862874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metazosin tablets (Kenosin) in the treatment of chronic congestive heart failure].
    Vokrouhlický L; Soucek R; Bílková A; Votavová M
    Cas Lek Cesk; 1995 Sep; 134(18):590-3. PubMed ID: 7489576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative first dose effects of prazosin and tiodazosin (BL-5111) in spontaneously hypertensive rats.
    Roebel LE; Florczyk AP; Buyniski JP
    Res Commun Chem Pathol Pharmacol; 1979 Jan; 23(1):29-35. PubMed ID: 441514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of reflex tachycardia by central administration of the alpha-1 adrenoceptor antagonists urapidil and prazosin in anesthetized dogs.
    Shebuski RJ; Zimmerman BG
    J Pharmacol Exp Ther; 1985 Aug; 234(2):456-62. PubMed ID: 2862276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacology of antihypertensive drugs with special reference to vasodilators, alpha-adrenergic blocking agents and prazosin.
    Cambridge D; Davey MJ; Massingham R
    Med J Aust; 1977 Aug; 2(1 Suppl):2-6. PubMed ID: 21341
    [No Abstract]   [Full Text] [Related]  

  • 11. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
    Armah BI; Hofferber E; Stenzel W
    Arzneimittelforschung; 1988 Oct; 38(10):1426-34. PubMed ID: 3196383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs.
    Sironi G; Montagna E; Greto L; Bianchi G; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Feb; 46(2):145-52. PubMed ID: 8720303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade.
    Constantine JW; Lebel W; Weeks R
    J Cardiovasc Pharmacol; 1984; 6(1):142-50. PubMed ID: 6199597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cardiac effects of hypotensive agents in normotensive mature rats: comparison of beta-blocking agent and converting enzyme inhibition.
    Azizi M; Levy B; Salzmann JL; Cerol ML; Poitevin P; Ménard J; Michel JB
    J Cardiovasc Pharmacol; 1989 May; 13(5):691-701. PubMed ID: 2472516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological and toxicological properties of ryodipine.
    Kimenis AA; Vitolina RO; Petersone IO; Germane SK; Briede JL
    Arzneimittelforschung; 1985; 35(4):672-9. PubMed ID: 4015733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of a new antihypertensive agent in several species.
    Salvati P; Caravaggi AM; Lamberti E; Monteggia M; Bianchi G
    Arzneimittelforschung; 1983; 33(8):1098-106. PubMed ID: 6685486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic and regional hemodynamic effect of acute magnesium administration in the normotensive and hypertensive state.
    DiPette DJ; Simpson K; Guntupalli J
    Magnesium; 1987; 6(3):136-49. PubMed ID: 3626625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The pharmacodynamic and hypotensive efficacy of proxodolol in an acute drug test on hypertension patients].
    Kukes VG; Starodubtsev AK; Smirnov MV; Petrov IN
    Eksp Klin Farmakol; 1994; 57(3):45-7. PubMed ID: 7914120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.